香港股市 已收市

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
33.54+0.12 (+0.36%)
收市:04:00PM EST
32.88 -0.66 (-1.97%)
收市後: 07:40PM EST
全螢幕
交易股價資料並非來自所有市場
前收市價33.42
開市33.42
買盤0.00 x 1200
賣出價0.00 x 800
今日波幅31.84 - 33.70
52 週波幅12.40 - 44.19
成交量1,310,671
平均成交量2,176,903
市值4.852B
Beta 值 (5 年,每月)0.71
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-1.96
業績公佈日2024年2月01日 - 2024年2月05日
遠期股息及收益率無 (無)
除息日
1 年預測目標價49.08
  • Insider Monkey

    15 Best-Performing Stocks in the Last 12 Months

    In this article, we will take a look at the 15 best-performing stocks in the last 12 months. To see more such companies, go directly to 5 Best-Performing Stocks in the Last 12 Months. The US stock market has been performing unusually well in 2023. The most recent catalyst came after the Federal Reserve’s fight […]

  • InvestorPlace

    The Quant Trading System Picking Stocks That Soar 300%

    Editor’s note: “The Quant Trading System Picking Stocks That Soar 300%” was previously published in January 2023. It has since been updated to include the most relevant information available. The stock market got crushed in 2022. It was a nasty year for most investors. But what if I told you that amid 2022’s financial market turmoil, there was a quantitative trading system that was regularly picking stocks that were soaring 100%, 200%, and even 300%-plus in a matter of months? InvestorPlace - St

  • Benzinga

    Immunovant Could Potentially Be An M&A Target, Writes Analyst

    Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Overweight rating and a price target of $30. The company's pipeline includes batoclimab (IMVT-1401) and IMVT-1402, fully human, monoclonal antibodies targeting the neonatal fragment crystallizable receptor (FcRn). Batoclimab has demonstrated its potential to reduce immunoglobulin G (IgG) antibodies that cause inflammation, while IMVT-1402 has also demonstrated profound IgG antibody reduction in animal studies. Related: